Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease
Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, announced it has initiated dosing in a Phase 1 clinical trial…
Read More...
Read More...
